Myths About BPC-157: What the Evidence Really Shows

BPC-157 has become one of the most talked-about peptides in gyms and online communities, promoted as a near-miraculous healer for tendons, joints and the gut. The reality is far more modest. Our editorial team separates the popular claims from what published research can and cannot support.

Where BPC-157 comes from

BPC-157 stands for "Body Protection Compound 157". It is a synthetic chain of 15 amino acids, a pentadecapeptide, derived from a sequence identified in a protein found in human gastric juice. Most of the early research came from a single group of investigators in Zagreb, Croatia, who published a large number of animal studies from the 1990s onwards.

Those experiments, mostly in rats, reported faster healing of stomach ulcers, tendons, ligaments, muscles and even bone after the peptide was given by injection or in drinking water. Proposed mechanisms include stimulation of new blood vessel growth, interaction with the nitric oxide system and increased expression of growth hormone receptors in tendon cells.

These findings are interesting from a laboratory point of view. However, the concentration of research in one centre, combined with very limited independent replication, is a weakness that reviewers have repeatedly highlighted. Laboratory enthusiasm has travelled much faster than clinical validation.

BPC-157 has never been authorised as a medicine by the MHRA, the European Medicines Agency or the US Food and Drug Administration. There is no licensed product, no approved indication and no official dose for humans.

Myth 1: 'It is proven to heal injuries in humans'

This is the most widespread claim and the least supported. Systematic reviews of BPC-157 for musculoskeletal healing, such as the one by Gwyer and colleagues (2019), conclude that the evidence is almost entirely preclinical. Rodent models of cut or crushed tendons do not reproduce chronic tendinopathy in a 35-year-old runner.

Published human data are extremely limited. One frequently cited paper is a small retrospective report of knee pain treated with intra-articular injections (Lee and Padgett, 2021), with no control group and no blinding. Such reports can generate hypotheses, but they cannot prove that the peptide, rather than time, rest or placebo, caused the improvement.

Some early-phase clinical trials were registered years ago, notably for inflammatory bowel disease, but full peer-reviewed results demonstrating efficacy in people have not been published. Absence of evidence is not proof of failure, yet it is certainly not proof of success either.

When someone says BPC-157 "fixed" their shoulder, it is worth remembering that most soft-tissue injuries improve naturally over weeks to months, and that anecdotal reports are strongly shaped by expectation and by the simultaneous use of physiotherapy.

Myth 2: 'It is natural, so it must be safe'

The argument runs like this: the peptide is based on a sequence from gastric juice, therefore the body already "knows" it. In reality, BPC-157 as sold is a laboratory-made molecule, and the stable form used in studies does not occur freely in the bloodstream in measurable amounts.

More importantly, "natural" says nothing about safety. Insulin, adrenaline and cortisol are natural too, yet all can be dangerous in the wrong dose. The proposed mechanism of BPC-157, promoting angiogenesis, raises a theoretical concern: new blood vessel growth is also a process that tumours exploit. No human data exist to rule this out over long-term use.

Formal toxicology packages of the type required for a medicine, including long-term carcinogenicity and reproductive studies, have not been made public. Animal experiments reporting no obvious toxicity used short durations and small numbers.

In 2023 the US FDA placed BPC-157 among bulk substances that compounding pharmacies should not use, citing insufficient safety information and potential immunogenicity. That decision does not apply directly in the UK, but it reflects the same concern about missing data.

Myth 3: 'Research peptides are pure and legal'

Products labelled "for research purposes only, not for human consumption" are sold in a legal grey zone. In the UK, supplying an unlicensed medicine for human use is regulated under the Human Medicines Regulations 2012, and the "research" label does not change what the product is actually being sold for.

Independent analyses of grey-market peptides have repeatedly found wrong concentrations, degraded material, bacterial endotoxins and, at times, an entirely different substance. Injecting a non-sterile powder reconstituted at home adds the risk of abscesses and infection.

For tested athletes, the situation is unambiguous. BPC-157 is explicitly named by WADA under section S0, non-approved substances, which are prohibited at all times. UK Anti-Doping has sanctioned athletes for its use, and ignorance of the rules is not accepted as a defence.

What actually helps soft-tissue healing

For tendon and ligament problems, the best supported interventions are much less glamorous. Progressive loading programmes guided by a physiotherapist, especially heavy slow resistance and eccentric work for tendinopathies, have far more robust trial data than any peptide.

Adequate total protein intake, generally around 1.6 g per kilogram of body weight per day for people who train hard, supports tissue repair. Some studies suggest that gelatine or collagen combined with vitamin C taken before loading may support collagen synthesis, though the evidence remains early.

• Get an accurate diagnosis, ideally with clinical examination and, when needed, ultrasound or MRI.
• Modify rather than stop training, keeping pain at an acceptable level.
• Prioritise sleep and overall energy intake.
• Be patient: tendon remodelling takes months, not days.

Persistent or worsening pain, swelling, loss of function or numbness deserves medical assessment. Self-injecting an unlicensed peptide can mask symptoms while the underlying problem progresses.

Editorial conclusions

BPC-157 has an intriguing body of animal research, but there is still no convincing controlled evidence that it heals injuries in humans.

Claims of natural safety, purity and legality do not hold up: long-term safety is unknown, grey-market quality is unreliable and the substance is banned in sport.

Evidence-based rehabilitation, adequate nutrition and time remain the foundation of recovery from soft-tissue injury.

For further reading, our editorial team suggests articles on how WADA classifies non-approved substances, the evidence behind collagen supplements for joints, and the risks of injecting unregulated products.

References

1. Gwyer D, Wragg NM, Wilson SL. Gastric pentadecapeptide body protection compound BPC 157 and its role in accelerating musculoskeletal soft tissue healing. Cell Tissue Res. 2019;377(2):153–159.
2. Seiwerth S, Rucman R, Turkovic B, et al. BPC 157 and standard angiogenic growth factors. Gastrointestinal tract healing, lessons from tendon, ligament, muscle and bone healing. Curr Pharm Des. 2018;24(18):1972–1989.
3. Chang CH, Tsai WC, Lin MS, Hsu YH, Pang JH. The promoting effect of pentadecapeptide BPC 157 on tendon healing involves tendon outgrowth, cell survival, and cell migration. J Appl Physiol. 2011;110(3):774–780.
4. Lee E, Padgett B. Intra-articular injection of BPC 157 for multiple types of knee pain. Altern Ther Health Med. 2021;27(4):8–13.
5. World Anti-Doping Agency. World Anti-Doping Code International Standard: Prohibited List 2025. Montreal: WADA; 2025.
6. Beyer R, Kongsgaard M, Hougs Kjær B, et al. Heavy slow resistance versus eccentric training as treatment for Achilles tendinopathy: a randomized controlled trial. Am J Sports Med. 2015;43(7):1704–1711.